The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Gynecologic Cancer Case Studies

Krishnansu S. Tewari, MD, FACOG, FACS: Options to Controlling Recurrent Metastatic Disease

Krishnansu S. Tewari, MD, FACOG, FACS
Published Online:Jun 16, 2015
Sarah W. is a 62-year-old Caucasian woman who works as a travel agent.

Gynecologic Cancers: Case 1

Gynecologic Cancers: Case 1
Gynecologic Cancers: Case 2

Krishnansu S. Tewari, MD, FACOG, FACS says that since this patient is platinum-sensitive, options include cisplatin, carboplatin, or oxaliplatin combined with either gemcitabine, pegylated liposomal doxorubicin, or topotecan. Although not FDA-approved for platinum- sensitive patients, bevacizumab at 15 mg/kg has been shown to improve PFS in platinum-sensitive patients in the OCEANS study when combined with carboplatin plus gemcitabine. Since she has had a long disease-free interval of 3 years and appears on imaging to only have surface liver metastasis and a solitary splenic nodule, a consideration for laparoscopy could be entertained with plans to perform a secondary cytoreductive surgery with or without heated intraperitoneal chemotherapy if limited disease is indeed encountered.

CASE 1: Epithelial Ovarian Cancer

Sarah W. is a 62-year-old Caucasian woman who works as a travel agent.

In June of 2013, the patient presented with bloating and abdominal distension. Prior medical history is notable for nulliparity, and medication-controlled hypertension.
  • Physical exam revealed palpable, fixed nodular 10-cm pelvic mass with abdominal ascites, and patient’s CA-125 level was 895 U/mL
  • She underwent total abdominal hysterectomy, bilateral salpingo oophorectomy, omentectomy, low anterior resection with anastomosis and complete cytoreduction of all gross metastatic disease. There was no gross residual disease. Stage was FIGO 3C epithelial ovarian cancer
  • Patient was negative for BRCA1 or 2 mutation
  • She received 6 IV q3-week cycles of paclitaxel/carboplatin
  • Her symptoms resolved and CA-125 levels decreased to 9 U/mL; she remained disease free for approximately 18 months
In December of 2014, the patient presents for her 6-month evaluation with rising CA-125 level, mild abdominal distension and fatigue, and inability to work.
  • CT scanning reveals metastatic involvement of liver surface, an isolated splenic lesion, and a small amount of ascites
  • She was retreated with carboplatin/paclitaxel
  • Patient showed improvement in symptoms and performance status (ECOG 0) after 3 cycles of therapy
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.